Drug interaction is a phenomenon that has to be thoroughly investigated in order to avoid adverse effects. This review article highlights the drug interaction of oral hypoglycemics by mechanism of cytochrome P450 enzyme inhibition. Approach: Published articles from PubMed and other sources were used to review and compile these drug interaction studies. Findings: Drug interaction in oral hypoglycemics by mechanism of cytochrome P450 enzyme inhibition can increase the risk of hypoglycemia in diabetic patients and hence dose adjustments may be required. Conclusion: These drug interaction studies are essential for patients suffering from diabetes mellitus as it prevents the risk of occurrence of hypoglycemia. This information is also important for the prescribing physicians as dose alteration or alternate drugs need to administered in case of concomitant administration of drugs in case of polypharmacy.

Prognosis for individuals with beta-thalassemia has improved substantially in the last 20 years. However, cardiac disease remains the main cause of death in patients with iron overload. Induced pluripotent stem cells, prenatal diagnosis, oral sodium phenyl butyrate therapy,drugs such as Deferoxamine , Deferasirox (ICL670), Deferiprone which are clinical trials are new approaches to treat beta thalassemia.